SunTrust’s Robyn Karnauskas is over-the-top bullish on thinly traded micro cap BioXcel Therapeutics (NASDAQ:BTAI) with her $150 (529% upside) price target, an upward revision of 525%.
She says “greater due diligence” revealed added
sales in opioid withdrawal and revised sales potential in dementia,
schizophrenia and bipolar disorder, adding that investors are “missing
the potential” for the impact of results from four clinical trials (two
pivotal and two Phase 2s) to “shift the company’s dynamics.”
The stock is up about six-fold since early November 2019.
Shares up 76% premarket on increased volume.
https://seekingalpha.com/news/3542218-bioxcel-up-76-premarket-suntrust-beats-drum-on-potential-upside
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.